Education
About Us
Working with TipRanks
Follow Us
Human Metabolome Technologies, Inc. (JP:6090)
:6090
6090 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥501.00 - ¥869.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.78K
Market Cap
¥4.65B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.4
Beta0.38
Next Earnings
Aug 08, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 27, 2025Dividend Yield1.94%
Share Statistics
EPS (TTM)35.78
Shares Outstanding5,919,797
10 Day Avg. Volume8,440
30 Day Avg. Volume10,780
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥922.00Price Target Upside17.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥501.00 and its highest was ¥869.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥4.65B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Aug 08, 2025 which is in 6 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on May 14, 2025. The company reported ¥35.78 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.78.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Undervalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥15 which represents an annual dividend yield of 1.94%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥35.78 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.737%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Technical Analysis
Soiken Holdings Inc.
―
Shin Nippon Biomedical Laboratories, Ltd.
―
DNA Chip Research Inc.
―
Kainos Laboratories, Inc.
―
Immuno-Biological Laboratories Co., Ltd.
―
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---